{"id":"W4387809927","doi":"10.1016/j.annonc.2023.09.3100","title":"354TiP A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2– early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Seagen; Relay Therapeutics; Incyte; Daiichi-Sankyo; Pfizer; Genentech; Mersana Therapeutics; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Adjuvant therapy; Oncology; Tamoxifen; Fulvestrant; Breast cancer; Adjuvant; Aromatase inhibitor; Hazard ratio; Cancer; Trastuzumab; Surgery; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008552192,0.00142241,0.002039839,0.0003838383,0.0002848551,0.001042234,0.0007982848,0.001439198,0.01480851],"category_scores_gemma":[0.001022053,0.0005760816,0.001647581,0.0003353886,0.0009729841,0.0007848708,0.0003422668,0.003132532,0.00183469],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005782083,"about_ca_system_score_gemma":0.0009963096,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001152292,"about_ca_topic_score_gemma":0.002322901,"domain_scores_codex":[0.9996517,0.0001844976,0.0000170896,0.00005271768,0.00002035431,0.00007363899],"domain_scores_gemma":[0.9994764,0.0001588694,0.00007208403,0.00004896945,0.00002572204,0.0002179437],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9774677,0.006407522,0.0002847536,0.0002785327,0.0004631989,0.00002660611,0.00002771282,0.0003483189,0.002791394,0.0001143358,0.0006405555,0.01114941],"study_design_scores_gemma":[0.9213741,0.07589518,0.001065924,0.00001701184,0.0002386855,0.00002103057,0.00001515976,0.0003477316,0.0002672733,0.0001315222,0.0006159842,0.00001047106],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856619,0.002987009,0.0007406993,0.0007157243,0.0006637787,0.002804746,0.00216406,0.0001767182,0.004085345],"genre_scores_gemma":[0.9795346,0.002388546,0.00210466,0.00152939,0.0005335552,0.003084402,0.002918291,0.00003912262,0.007867468],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01480851,"threshold_uncertainty_score":0.04953939,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06015312760793879,"score_gpt":0.4174183995271137,"score_spread":0.3572652719191749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}